top of page



The MedSIR Project Development team attended the 2019 Genitourinary (GU) Cancers Symposium held in San Francisco, CA on February 14-16. It was a great opportunity to meet our scientific collaborators, business partners, and friends, and catch up with the latest news and developments in the genitourinary cancer space.

Highlights of this year´s ASCO GU include:

Final analysis of the LATITUDE phase III study was presented. Treatment with abiraterone acetate and prednisone with androgen deprivation therapy (ADT) in men with newly-diagnosed, castration sensitive, metastatic prostate cancer continues to demonstrate a significant OS advantage than ADT alone.

Efficacy and safety data of the ARAMIS study, which looks at darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC), was presented. Based on these results, darolutamide appears safe and effective for men with nmCRPC, increasing both metastasis-free survival and overall survival at this interim analysis. Darolutamide will be the third drug to join the nmCRPC space, along with apalutamide and enzalutamide.

Data from the phase 3 ARCHES trial shows that enzalutamide significantly improved radiographic progression-free survival in men with metastatic hormone-sensitive prostate cancer.

The JAVELIN Renal 101 subgroup analysis demonstrated longer PFS and higher ORR with avelumab plus axitinib compared to sunitinib for treatment-naïve patients with advanced RCC.

Treatment with chemotherapy and radiotherapy after surgery improves disease free survival and overall survival in advanced urothelial carcinoma as demonstrated by results from a randomized phase III trial of adjuvant sequential chemotherapy plus radiotherapy versus adjuvant radiotherapy alone for locally advanced bladder cancer after radical cystectomy.

ASCO GU 2019 was a great, successful meeting and we can´t wait till next year to see what new advances in the treatment of genitourinary cancers are presented! These are indeed exciting times!



bottom of page